Related Experiment Videos
Cardiovascular Complications Associated With Novel Cancer Immunotherapies
Varun Jain1,2, Jaspreet Bahia2, Mahsa Mohebtash3
1MedStar Washington Hospital Center, Washington, DC, USA.
Opinion Statement:
Immune therapies represent a quantum leap in the fight against cancer. Recently approved immune checkpoint inhibitors that target receptors involved in immune escape of cancer cells (including cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1) are increasingly being used for therapeutic benefit in a number of cancers. The robust anti-cancer activity of these agents has been accompanied by the recognition of new adverse effects, often due to the over activation of immune system, that may limit their therapeutic benefit and adversely impact outcomes. Combination treatments in particular, such as approaches using two targeted immunotherapy agents, have higher risk of adverse effects. Our review focuses on the approved checkpoint inhibitor therapies and their potential for cardiovascular toxicity. While very few cases of autoimmune cardiotoxicity and myocarditis have been reported in clinical trials, severe, life-threatening episodes of heart failure and hemodynamic compromise associated with the use of immune checkpoint inhibitors have recently been reported in the literature. Early recognition, diagnosis, and management of autoimmune myocarditis represent an important clinical challenge with no current guidelines available for prevention, identification, and treatment of this serious condition. This area of cardio-oncology is evolving rapidly as more drugs in this class are being discovered and pending approval. There is a need for future studies focused on prospective identification of biomarkers and clinical standards for treatment and long-term follow-up of cardiovascular toxicity to successfully continue the treatment of cancer while preventing the adverse outcomes with novel immune therapies.
Insights
Immune checkpoint inhibitors improve cancer treatment but can cause severe heart problems like myocarditis. Early detection and management are crucial for patient safety and continued therapy.
Area of Science:
- Cardio-oncology
- Immunotherapy
- Cardiovascular Toxicity
Background:
- Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1 offer significant cancer treatment benefits.
- ICI therapy can lead to immune-related adverse events due to immune system overactivation.
- Cardiovascular toxicity, including myocarditis, is a serious concern with ICI use, particularly in combination therapies.
Purpose of the Study:
- To review approved immune checkpoint inhibitor therapies.
- To focus on the potential for cardiovascular toxicity associated with these therapies.
- To highlight the urgent need for guidelines in managing ICI-induced cardiotoxicity.
Main Methods:
- Review of approved immune checkpoint inhibitor therapies.
- Analysis of reported cases of cardiovascular toxicity in the literature.
- Focus on autoimmune cardiotoxicity and myocarditis.
Main Results:
- While rare in clinical trials, severe cardiotoxicity and myocarditis have been increasingly reported with ICI use.
- Combination ICI treatments may carry a higher risk of adverse cardiovascular events.
- Lack of established guidelines for prevention, identification, and treatment of ICI-induced myocarditis.
Conclusions:
- Autoimmune myocarditis is a significant and potentially life-threatening adverse effect of immune checkpoint inhibitors.
- Early recognition, diagnosis, and management are critical challenges in cardio-oncology.
- Future research should focus on biomarkers, clinical standards, and long-term follow-up for cardiovascular toxicity.